Barclays Maintains Equal-Weight on Teladoc Health, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Neutral 65.3%

Neg 0% Neu 65.3% Pos 0%

Barclays analyst Glen Santangelo maintains Teladoc Health (NYSE:TDOC) with a Equal-Weight and lowers the price target from $8.5 to $7.